14th Annual Highlights of ASCO Recorded Session
This program is designed for physicians, PAs, nurse practitioners, registered nurses, medical staff and pharmacists in Wisconsin and neighboring states wanting to learn about the latest updates in cancer treatment. The conference is designed to review the current clinical updates from the American Society of Clinical Oncology (ASCO) annual meeting. The conference will educate regarding practice-changing findings presented at ASCO 2021.
If you attended any the live session of 14th Annual Highlights of ASCO, you will not be able to claim credit again. You can, however, still watch the content.
This course is intended for physicians, PAs, nurse practitioners, registered nurses, medical staff and pharmacists in Wisconsin and neighboring states wanting to learn about the latest updates in cancer treatment.
At the end of this session, learners should be able to:
- Review highlights of the advances in clinical and translational research presented at the 2021 ASCO® annual meeting
- Identify emerging trends and strategies designed to improve the quality of symptom management and survivorship care
- Evaluate tools and resources in specific areas of cancer management that can be used to achieve effective cancer care delivery and improve the patient experience
Michael P. Mullane, MD, Medical Oncologist, Aurora Cancer Care Medical Director, Hereditary Cancer Prevention and Management Center; Advocate Aurora Health
James Weese, MD, FACS, Vice President of Aurora Cancer Care and Clinical Adjunct Professor of Surgery UW School of Medicine & Public Health, Aurora Cancer Care; Advocate Aurora Health
Federico A. Sanchez, MD, System Medical Director, Medical Oncology, Aurora Cancer Care; Advocate Aurora Health
Michael A. Thompson, MD, PhD, FASCO, Medical Director, Early Phase Cancer Research Program Medical Co-Director, Oncology Precision Medicine Program; Advocate Aurora Health
Rubina Qamar, MD, Medical Oncologist, Aurora Cancer Care; Advocate Aurora Health
Jon Richards, MD, Oncology/Hematology Center for Advanced Care; Advocate Aurora Health
Lawrence Einhorn, MD, Livestrong Foundation Professor of Oncology, Distinguished Professor of Medicine, Department of Medicine, Indiana University
Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology Department of Medical Oncology, Dana-Farber Cancer Institute; Co-Leader, Kidney Cancer Program, Dana-Farber/Harvard Cancer Center; Jerome and Nancy Kohlberg Professor of Medicine Harvard Medical School
Nina Shah, MD, Professor, Clinical Medicine, Hematology-Oncology, University of California San Francisco
Kari Braun Wisinski, MD, Professor of Medicine, Interim Chief, Division of Hematology, Medical Oncology and Palliative Care, UW School of Medicine and Public Health, UW Carbone Cancer Center
Christina Wu, MD, GI Oncology, Associate Professor of Hematology/Oncology; Assoc. Div. Director of Medical Oncology Winship Cancer Institute, Emory University
Amy Bock, Senior Director Clinical Program Strategy; Advocate Aurora Health
Mary Walters, RN Specialist, Oncology program; Advocate Aurora Health
The following faculty speakers and/or planning committee members have disclosed the following:
Name of Ineligible Companies
Nature of Relationship
Michael Thompson, MD
-Adaptive; BMS (Celgene); GRAIL/Illumina; Syapse; Takeda
|Toni Choueiri, MD|
AstraZeneca; Aveo; Bayer; Bristol Myers-Squibb; Eisai; Exelixis; GlaxoSmithKline; IQVA; Ipsen; Lilly; Merck; Novartis; Pfizer; Roche; Sanofi/Aventis; Takeda; Tempest
|Nina Shah, MD||-Celgene/BMS; Janssen; Bluebird Bio; Sutro Biopharma; Teneobio; Poseida; Nektar|
-GSK; Amgen; Indapta Therapeutics; Sanofi; CareDx; Kite; Karyopharm; Oncopeptides
|Kari Wisinski, MD|
|-Study PI, advisory board|
-Advisory board, site PI
|Christina Wu, MD||-Vaccinex; Boston Biomedical Inc; Lycera; Seattle Genetics; Symphogen; FLX Bio (Rapt Therapeutics); INHBRX|
-PrecisCA; Oncology Learning Network
-Nova Research Company
-Site Principal Investigator
The other planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose. Conflict of interest have been identified and mitigated prior to the activity.
Advocate Aurora Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Advocate Aurora Health designates this enduring material for a maximum of 3.25 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 3.25 AMA PRA Category 1 Credit™Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 3.25 AttendanceAttendance Credit
- 3.25 Approved AMA PRA Category 1 Credit™